SUPN Supernus Pharmaceuticals
- 32.020
- +0.020+0.06%
Supernus Pharmaceuticals News
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GEMAYEL GEORGES
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khattar Jack A.
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khattar Jack A.
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bhatt Padmanabh P.
Supernus Pharmaceuticals | 8-K: Current report
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bhatt Padmanabh P.
Supernus Pharmaceuticals | 8-K: Supernus Announces Second Quarter 2024 Financial Results
Supernus Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 8-K: Current report
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 8-K: Current report
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Analysis
Price Target
No Data
No Data